Stevanato Group S.p.A. $STVN Stock: Conestoga Capital Advisors LLC Trims Position

Conestoga Capital Advisors LLC lessened its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 20.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,596,515 shares of the company’s stock after selling 1,411,098 shares during the period. Stevanato Group comprises approximately 3.6% of Conestoga Capital Advisors LLC’s holdings, making the stock its 7th largest holding. Conestoga Capital Advisors LLC’s holdings in Stevanato Group were worth $117,415,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new stake in Stevanato Group in the 2nd quarter worth approximately $59,000. State of Wyoming bought a new stake in shares of Stevanato Group in the 3rd quarter worth approximately $75,000. Fifth Third Bancorp grew its position in shares of Stevanato Group by 22.6% in the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after buying an additional 773 shares during the last quarter. Diversify Wealth Management LLC increased its stake in shares of Stevanato Group by 23.9% during the first quarter. Diversify Wealth Management LLC now owns 18,353 shares of the company’s stock valued at $252,000 after buying an additional 3,543 shares during the period. Finally, First Bank & Trust increased its stake in shares of Stevanato Group by 3.4% during the second quarter. First Bank & Trust now owns 18,417 shares of the company’s stock valued at $333,000 after buying an additional 603 shares during the period.

Insider Buying and Selling

In related news, CFO Marco Dal Lago sold 4,209 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total transaction of €84,558.81. Following the completion of the transaction, the chief financial officer owned 81,144 shares of the company’s stock, valued at €1,630,182.96. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elisabetta Magistretti sold 2,045 shares of Stevanato Group stock in a transaction on Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €41,084.05. Following the transaction, the director owned 2,930 shares of the company’s stock, valued at €58,863.70. The trade was a 41.11% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 21,926 shares of company stock valued at $459,738. 0.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on STVN. UBS Group decreased their target price on Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Stevanato Group in a report on Wednesday, October 7th. They issued a “hold” rating on the stock. William Blair cut shares of Stevanato Group from an “outperform” rating to a “market perform” rating in a report on Wednesday. Citigroup reduced their price objective on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Stevanato Group News Roundup

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% to €326.1 million. However, reported EPS was slightly below the consensus estimate in one earnings summary. Stevanato Group Q3 results
• Neutral Sentiment: Citigroup lowered its price target from $26 to $20 but kept a Buy rating, signaling reduced expectations while remaining positive on the shares. Citigroup price target update
• Negative Sentiment: Management said GLP-1-related revenue declined in Q3 to about 17%–18% of total revenue. The company also expects only low-single-digit growth in 2027, amid lower GLP-1 syringe volumes linked to one customer. 2027 growth outlook and GLP-1 volumes
• Negative Sentiment: UBS cut its price target from $23 to $16 and maintained a Neutral rating; William Blair downgraded the stock from Outperform to Market Perform. UBS price target update William Blair downgrade
• Negative Sentiment: Several law firms announced investigations into whether Stevanato complied with securities laws, following its GLP-1 revenue disclosure. These are investigations, not findings of wrongdoing, but may add legal and reputational uncertainty. Investor investigation announcement

Stevanato Group Trading Down 1.2%

Shares of NYSE STVN opened at €13.29 on Thursday. Stevanato Group S.p.A. has a 1 year low of €12.05 and a 1 year high of €27.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The firm has a 50-day moving average of €20.17 and a 200 day moving average of €18.07. The stock has a market cap of $4.02 billion, a P/E ratio of 22.91, a price-to-earnings-growth ratio of 1.16 and a beta of 0.80.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 earnings per share for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). Stevanato Group had a return on equity of 10.62% and a net margin of 11.24%. The business had revenue of €326.06 million during the quarter. As a group, sell-side analysts expect that Stevanato Group S.p.A. will post 0.69 EPS for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.